Check for updates

OPEN ACCESS

EDITED BY Gang Chen, Shenyang Pharmaceutical University, China

REVIEWED BY Lina Fang, Shenyang Medical College, China Li Bo Wang, Harbin Medical University, China

*CORRESPONDENCE Ning Zhang, ⊠ cmuzn@sohu.com

RECEIVED 10 April 2024 ACCEPTED 08 May 2024 PUBLISHED 22 May 2024

CITATION

Zhang Z, Li Y, Wu J, Zhang J, Chen N and Zhang N (2024), Therapeutic effect of *Periploca forrestii* on collagen-induced arthritis in rats through JAK2/NF- κ B pathway. *Front. Pharmacol.* 15:1415392. doi: 10.3389/fphar.2024.1415392

COPYRIGHT

© 2024 Zhang, Li, Wu, Zhang, Chen and Zhang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Therapeutic effect of *Periploca* forrestii on collagen-induced arthritis in rats through JAK2/ Nf-κB pathway

Zhenyi Zhang¹, Yingchun Li¹, Jian Wu², Jihong Zhang¹, Ning Chen² and Ning Zhang¹*

¹Department of Rheumatology and Immunology, Shengjing Hospital of China Medical University, Shenyang, China, ²College of Pharmacology, Harbin University of Commerce, Harbin, China

Background: Rheumatoid arthritis (RA) is a chronic autoimmune disease that affects the body. *Periploca forrestii* was a *miao* ethnic drug in China that was used to treat arthritis for hundreds of years. But, the therapeutic mechanism is so far unknown. Therefore, the chemical component and effect of *Periploca forrestii* on arthritis in rats were studied using HPLC-QTOF MS, micro-CT, and other experiments in this paper.

Method: Male Sprague-Dawley rats were used to assess the *in vivo* activity. HPLC QTOF-MS was used to analyze the chemical profile of the *P. forrestii* (PF). Bovine type II collagen and Complete Freund's Adjuvant were used to stimulate and construct the collagen-induced arthritis (CIA) model. Three dosages of PF (100 mg/kg, 200 mg/kg, 400 mg/kg) were used to evaluate *in vivo* activity. Methotrexate was used as the positive drug. H/E staining and micro-CT methods were used to assess the serum level of immune- and inflammation-related cytokines. Immunohistochemical experiments were used to test the gene expression in JAK and Nf-κB pathways.

Results: 42 compounds were identified from PF. PF administration lowered the increased spleen index compared with that of control and MTX groups, and partially restored body weight, reduced paw swelling, and arthritis score compared with the model group. Macroscopic assessment indicated inflamed paw with significant swelling in the model group, while the extent of inflammation and swelling was attenuated by both MTX and PF. H/E staining experiments demonstrated that pathological changes of synovial cells and infiltration of inflammatory cells were observed in the model group. In contrast, the MTX and PF treatment partially reversed these pathological changes. Micro-CT examination showed severe injuries and scars caused by inflammation for the model group, and in the high-dosage group (400 mg/kg) the inflammation-caused injuries and scars were dramatically ameliorated. Mechanism study showed that PF restored Nf- κ B phosphorylation and JAK2 expression compared with the model group.

Conclusion: *P. forrestii* possesses a potent effect on CIA rats. Nf- κ B and JAK2 pathways are involved in its protective effect on CIA.

KEYWORDS

Periploca forrestii, arthritis, micro-CT, JAK2, NF-κB

1 Introduction

Rheumatoid arthritis (RA) is a chronic autoimmune disease that affects the entire body. It causes swelling, inflammation, and even damage to the cartilage at the joints, which can make it difficult for people to perform daily activities. Unfortunately, the number of people suffering from RA is increasing worldwide, with up to 1% of the population being diagnosed every year (McInnes and Schett, 2017). In the past few decades, the main treatment for rheumatoid arthritis (RA) has been diseasemodifying antirheumatic drugs (DMARDs). Methotrexate is the most commonly used DMARD and is considered the first choice due to its high effectiveness and affordability. However, if RA cannot be managed or if there are negative side effects to DMARDs, biological agents and targeted drugs are prescribed instead (Smolen et al., 2023).

Periploca forrestii, a *miao* ethnic drug in China, is a sprawling shrub that can grow as long as 10 m. It belongs to the Asclepiadaceae family and is commonly found in mountain woodlands, typically in areas with limited exposure to sunlight or among shrubbery below an altitude of 2000 m. This particular plant has been found to contain a variety of natural chemical compounds, with a total of 124 phytochemicals having been isolated and identified thus far. Among these compounds, the cardiac glycosides are particularly noteworthy due to their ability to provide a range of health benefits. These benefits include anti-inflammatory properties, as well as the ability to promote wound healing (Chen et al., 2021).

The plant can be used for medicinal purposes, particularly for dispelling wind and eliminating dampness which are closely related to RA according to the traditional medicinal theory. Clinically, it is mainly used to treat RA and traumatic injury. It has earned the nickname "The king of all lianas" for its exceptional therapeutic effect on rheumatism. However, a solid-evidenced-based investigation of *P. forrestii* on RA is still absent. Previous studies on *P. forrestii* of silico investigation or experimental investigation of a part of this plant without a clear chemical profile only preliminarily implied its potential mechanism and effects on RA (Chen et al., 2017; Wang et al., 2022). Furthermore, the effect and mechanism of the whole plant of *P. forrestii* regarding the RA is still known, which is quite important an investigation as the whole plant of *P. forrestii* (PF) is used as a traditional medicine.

2 Materials and methods

2.1 Materials

The whole plant of *P. forrestii* was purchased from Beijing TRT Group in 2019. A voucher specimen (No. PF2020041602) was deposited at the China Medical University. Antibodies were purchased from Cell Signaling Technology (USA). Micro-CT (Quantum GX PerkinElmer) was used to evaluate the pathological changes of CIA rats. ELISA kits were purchased from Abcam. Agilent 1260 HPLC-6530 QTOF MS was used to analyze the chemical profile.

2.2 Chemical constituents identified from *Periploca forrestii* by LC-QTOF MS

Dried *P. forrestii* (1.0 g) was powdered and soaked in 70% methanol solution (v/v) for 1 h and extracted under ultrasonic conditions for 40 min at room temperature. The extraction was centrifuged at 3,000 rpm for 15 min and the supernatant was collected after filtering through 0.22 μ m membrane for HPLC-QTOF-MS analysis. Sample separation was carried on an Agilent 1260 HPLC system coupled with XBridge BEH C18 Column (5 μ m, 4.6 mm × 250 mm) with a mobile phase consisting of methanol containing 0.1% formic acid (A) and water 0.1% formic acid (B). Sample separation was achieved as gradient elution of 5%–100% (A, 0–60 min). Agilent 6530 QTOF MS was used to achieve the identification, positive and negative mode was used in the analysis and the injection volume was 10 μ L at the flow rate of 0.3 mL/min (25°C).

2.3 Preparation of Periploca forrestii

4.0 kg of PF was soaked in water of 10 times the volume for 1 h. After refluxing twice (1.5 h for each time), the extraction was combined and concentrated under vacuum to obtain the extract of *P. forrestii* (PF) for *in vivo* test. The extract was stored in a refrigerator at 4° C and was diluted with water before use.


2.4 In vivo evaluation

Male Sprague-Dawley (SD) rats $(200 \pm 20 \text{ g})$ were purchased from Liaoning Changsheng Biotechnology Co., Ltd. All experiments were conducted complying with the Guide of Care and Use of Laboratory Animals approved by Institutional Animal Ethics Committee in China Medical University (permission no. 200403011). On day 0, 0.1 mL aliquots of emulsifying agent CII (2 mg/mL) along with the same volume of CFA (1 mg/mL) were injected intradermally at the base of the tail and left sole, respectively, as the first immunization. On day 7, the second immunization was given. Rats of the normal group were injected with NaCl (0.9%). From day 3 onwards, all rats except the MTX group were orally given for 23 days, and three dosages of PF were 100 mg/kg (L), 200 mg/kg (M), and 400 mg/kg (H), respectively. The MTX group was orally administered one time every 2 days. The arthritis index was scored according to a previous report (Guma et al., 2009).

The index for indicated organs (%) = organ weight (g)/body weight (g)*100%.

2.5 Immunohistochemical assessment

Joint tissues were embedded in paraffin wax. Antibodies against rat JAK2 and p-NF- κ B were used to analyze the levels of JAK2 and p-NF- κ B expression in the ankle joint. The brown color represents the positive result.



2.6 Statistical analysis

Data are presented as the means \pm SEM. The difference was analyzed using Student's t-test and ANOVA, and p < 0.05 was considered statistically significant.

3 Results

3.1 Chemical profile of Periploca forrestii (PF)

The PF was analyzed by HPLC QTOF-MS for its components to afford basic peak chromatogram (Figure 1). A total of 42 chemical constituents were identified, with terpenoid and flavonoid being the major components (Supplementary Table S1).


3.2 Effect of PF on organ indexes

The immune system is a complex network of cells, tissues, and organs that work together to defend the body against harmful pathogens. Two of the most vital organs in the immune system are the spleen and thymus. To determine the effect of PF on the immunological function of these organs, the organs' relative weights are measured. Rats were sacrificed after the CIA model assessment, and their spleen, thymus, liver, and kidney were carefully weighed to calculate the organ indexes of each rat. The organ indexes provide an indication of the overall health of the immune system in the rats. The results showed that an evident disparity was observed between control and model (CIA) groups for spleen and thymus indexes. MTX slightly elevated the value of both spleen and thymus indexes, which might be the result of its side effects. Interestingly, PF administration could lower the spleen index compared with both control and MTX groups but failed to restore the thymus index compared with the model group. No alteration was observed for liver and kidney indexes (Figure 2).

3.3 PF elicits protective effects on CIA rats

To further understand the effect of PF on RA, the Body weight, paw swelling, and arthritis scores of each group were assessed. As a result, Both the positive drug and PF could restore the decreased body weight, ameliorate the paw swelling, and lower the arthritis score for the CIA mice (Figure 3A). Macroscopic assessment indicated an inflamed paw with significant swelling in the model group, while the extent of inflammation and swelling was attenuated by both MTX and PF (especially the high-dosage group) administration (Figure 3B). H/E staining assessment demonstrated a similar result, in which pathological changes of synovial cells and infiltration of inflammatory cells were observed in the model group while these pathological changes were partially reversed by the MTX and PF treatment (Figure 3C), suggesting that PF possesses a protective effect on CIA rats.

To further confirm the protective effect of PF, the micro-CT examination was conducted. The 3D computer-reconstructed results based on the micro-CT results (see Supplementary Data S1) showed severe injuries and scars caused by inflammation in



sections of joints for the model group, and in the high-dosage group (400 mg/kg) the inflammation-caused injuries and scars were dramatically ameliorated (Figure 4). All these results substantiated the protective effect of PF on CIA rats and provided a scientific basement for the clinical usage of PF regarding RA.

3.4 PF restores serum cytokines of CIA rats

To further explore the effect of PF on CIA rats, the immune- and inflammation-related cytokines in the serum of CIA rats were tested, including TNF- α , IL-1 β , IL-4, IL-6, IL-10, and IL-17 using the ELISA method. The upregulated levels for IL-1 β , TNF- α , IL-6, and IL-17 and downregulated levels for IL-4 and IL-10 were detected in the model group. Both MTX and PF administration could restore the ectopic profile of these immune- and inflammation-related serum cytokines (Figure 5).

3.5 PF restores Nf- κ B phosphorylation of CIA rats

 $Nf{-}\kappa B$ pathway is involved in the pathogenesis of several diseases. Studies have shown that $Nf{-}\kappa B$ pathway participates in


the therapeutic effect of a few traditional medicines (Li et al., 2022). We thus examined the expression of p-Nf- κ B using immunohistochemical method. The results showed that the phosphorylation of p-Nf- κ B was promoted in the model group while PF treatment partially restored the phosphorylation level of Nf- κ B (Figure 6).

3.6 PF restores JAK2 pathway of CIA rats

In addition to Nf- κ B pathway, we further tested the alteration in JAK2 pathway in CIA rats. The results showed that JAK2 expression was elevated in the model group (Figure 7). Similar to what was observed in the p-Nf- κ B, the ectopic expression of JAK2 was also partially rescued by PF treatment (Figure 7).

4 Discussion


P. forrestii is clinically used to treat arthritis, either used alone or in a compound prescription. However, as a plant-derived traditional medicine, its chemical component is, to a large extent, dominantly affected by the location and time of harvest, which determine the quality and thereby the bioactivity of *P. forrestii*. The whole plant of *P. forrestii* is used as a traditional medicine. Unfortunately, the




therapeutic effect of the whole plant of *P. forrestii* is so far absent, with only several reports of its stem extract or its specific components like saponins, which do not globally verify the effect and scientific basis for *P. forrestii* regarding its therapeutic effect on RA. On the other hand, several types of components have been identified from *P. forrestii*, including steroids, flavonoids, etc (Sun et al., 2017; Chen et al., 2018). The exact function and mechanism of these components in the *P. forrestii*-elicited therapeutic effect remain elusive. Therefore, more solid investigation should be performed to solve these questions. In this paper, we first verify

the function of the whole plant along with its chemical components in the treatment of CIA rats. The results showed that terpenoids and flavonoids are the major components of *P. forrestii*. Following this line of evidence, more studies on terpenoids and flavonoids should be conducted in future studies.

According to previous studies, six signal pathways are involved in the pathogenesis of RA, including MAPK, NF- κ B, PI3K, etc. In this paper, we in the first place found the alteration in the serum levels of IL-1 β , IL-17, TNF- α , etc. These cytokines can be modulated by MAPKs (McGeachy et al., 2019). Subsequently, we confirmed the







ectopic profile of these cytokines could be partially restored by PF treatment, suggesting that the MAPK pathway was involved in the therapeutic effect of PA.

Studies have demonstrated that the expression of NF- κ B is considerably higher in the synovial tissue of individuals with rheumatoid arthritis (RA). When NF- κ B is highly activated, it can stimulate the production of multiple proinflammatory cytokines, including TNF- α , IL-1 β , and IL-6. This, in turn, accelerates the progression of RA. Additionally, the upregulation of pro-inflammatory cytokines can positively regulate the activation of NF- κ B, thereby reinforcing a vicious cycle that further aggravates

RA progression (Noort et al., 2015). In this paper, we obtained a similar result that the abnormal phosphorylation in the CIA rats could be rescued by PF treatment.

RA is a chronic autoimmune disorder that affects joints, resulting in synovitis, which is characterized by inflammation of the synovial membrane. The synovial membrane in RA patients exhibits a range of inflammatory responses, including the activation of cytokines and adhesion molecules. These responses are related to specific transcription factors and signal transduction pathways. Research has shown that pro-inflammatory cytokines phosphorylate JAK, leading to the activation of the STAT





protein. Persistent inflammation and the severity of joint destruction in RA patients are linked to the transcription of STAT genes (Rosillo et al., 2016). In this paper, we found that JAK2 was the potential target of PF. Interestingly, JAK inhibitors are a recent discovery in the field of rheumatoid arthritis treatment. These targeted small molecules are designed to block the intracellular signaling that causes inflammation and joint damage. For example, tofacitinib is a particularly promising drug. It is a medication that specifically inhibits the JAK pathway, which is a key player in the inflammatory response. Developed in 2012, tofacitinib has been granted marketing approval by the US Food and Drug Administration. These results suggest that it is of great potential to explore novel JAK inhibitors from PF.

Data availability statement

The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found in the article/Supplementary Material.

Ethics statement

The animal study was approved by the Institutional Animal Ethics Committee of China Medical University. The study was

conducted in accordance with the local legislation and institutional requirements.

Author contributions

ZZ: Methodology, Writing-original draft. YL: Data curation, Writing-original draft. JW: Conceptualization, Data curation, Writing-original draft. JZ: Investigation, Writing-original draft. NC: Data curation, Methodology, Writing-original draft. NZ: Conceptualization, Writing-review and editing.

Funding

The author(s) declare that no financial support was received for the research, authorship, and/or publication of this article.

Acknowledgments

The authors thanks Prof Xiande Ma from Liaoning University of Tradition Chinese Medicine for his kind help in analyzed the micro-CT.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated

References

Chen, L., Li, J., Ke, X., Qu, W., Zhang, J., Feng, F., et al. (2017). The therapeutic effects of Periploca forrestii Schltr. Stem extracts on collagen-induced arthritis by inhibiting the activation of Src/NF-κB signaling pathway in rats. *J. Ethnopharmacol.* 202, 12–19. doi:10.1016/j.jep.2017.03.005

Chen, L., Li, J., Ke, X., Sun, C., Huang, X., Jiang, P., et al. (2018). Chemical profiling and the potential active constituents responsible for wound healing in Periploca forrestii Schltr. J. Ethnopharmacol. 224, 230–241. doi:10.1016/j.jep.2018.04.023

Chen, L., Tang, S., Li, X., Kuang, Y., Huang, H., Fan, P., et al. (2021). A review on traditional usages, chemical constituents and pharmacological activities of periploca forrestii schltr. J. Ethnopharmacol. 271, 113892. doi:10.1016/j.jep.2021.113892

Guma, M., Ronacher, L., Liu-Bryan, R., Takai, S., Karin, M., and Corr, M. (2009). Caspase 1-independent activation of interleukin-1beta in neutrophil-predominant inflammation. *Arthritis Rheum.* 60, 3642–3650. doi:10.1002/art.24959

Li, Y., Liang, Q., Zhou, L., Cao, Y., Yang, J., Li, J., et al. (2022). An ROS-responsive artesunate prodrug nanosystem co-delivers dexamethasone for rheumatoid arthritis treatment through the HIF-1α/NF-κB cascade regulation of ROS scavenging and macrophage repolarization. *Acta Biomater.* 152, 406–424. doi:10.1016/j.actbio.2022. 08.054

Mcgeachy, M. J., Cua, D. J., and Gaffen, S. L. (2019). The IL-17 family of cytokines in health and disease. *Immunity* 50, 892–906. doi:10.1016/j.immuni.2019.03.021

organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fphar.2024.1415392/ full#supplementary-material

Mcinnes, I. B., and Schett, G. (2017). Pathogenetic insights from the treatment of rheumatoid arthritis. *Lancet* 389, 2328–2337. doi:10.1016/s0140-6736(17)31472-1

Noort, A. R., Tak, P. P., and Tas, S. W. (2015). Non-canonical NF- κB signaling in rheumatoid arthritis: dr jekyll and mr hyde? Arthritis Res. Ther. 17, 15. doi:10.1186/s13075-015-0527-3

Rosillo, M. A., Sánchez-Hidalgo, M., Sánchez-Fidalgo, S., Aparicio-Soto, M., Villegas, I., and Alarcón-De-La-Lastra, C. (2016). Dietary extra-virgin olive oil prevents inflammatory response and cartilage matrix degradation in murine collagen-induced arthritis. *Eur. J. Nutr.* 55, 315–325. doi:10.1007/s00394-015-0850-0

Smolen, J. S., Landewé, R. B. M., Bergstra, S. A., Kerschbaumer, A., Sepriano, A., Aletaha, D., et al. (2023). EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. *Ann. Rheum. Dis.* 82, 3–18. doi:10.1136/ard-2022-223356

Sun, C. L., Chen, L., Xu, J., Qu, W., Guan, L., Liu, W. Y., et al. (2017). Melanogenesisinhibitory and antioxidant activities of phenolics from Periploca forrestii. *Chem. Biodivers.* 14, e1700083. doi:10.1002/cbdv.201700083

Wang, Q., Yao, X., Ling, Y., Huang, Y., Chen, C., Hou, L., et al. (2022). Investigation of the mechanism of periploca forrestii against rheumatoid arthritis with network pharmacology-based analysis. *Evid. Based Complement. Altern. Med.* 2022, 2993374. doi:10.1155/2022/2993374